Phase patients receive oral imatinib mesylate. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy7

K562 Cells Philadelphia Chromosome Cell Line, Tumor Chromosomes, Human, Pair 9 Neoplastic Stem Cells Myeloid Progenitor Cells Cells, Cultured

Diseases23

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Gastrointestinal Stromal Tumors Leukemia, Myeloid, Chronic-Phase Blast Crisis Hypereosinophilic Syndrome Hypopigmentation Gastrointestinal Neoplasms Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Philadelphia Chromosome Dermatofibrosarcoma Mastocytosis, Systemic Fibromatosis, Aggressive Leukemia, Myeloid, Accelerated Phase Lichenoid Eruptions Neoplasm, Residual Primary Myelofibrosis Disease Progression Recurrence Scleroderma, Systemic Histiocytoma, Malignant Fibrous Precursor Cell Lymphoblastic Leukemia-Lymphoma Fibrosis Graves Ophthalmopathy

Chemicals and Drugs31

Benzamides Piperazines Pyrimidines Fusion Proteins, bcr-abl Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Receptor, Platelet-Derived Growth Factor beta Proto-Oncogene Proteins c-abl Protein-Tyrosine Kinases Receptors, Platelet-Derived Growth Factor Enzyme Inhibitors Pregnatrienes Thiazoles Proto-Oncogene Proteins c-sis Harringtonines Interferon-alpha mRNA Cleavage and Polyadenylation Factors Ketones Furans Pyrroles Rifabutin Hydroxyurea STAT5 Transcription Factor Platelet-Derived Growth Factor Stem Cell Factor RNA, Messenger Indoles Oncogene Proteins, Fusion Antigens, CD34

Analytical, Diagnostic and Therapeutic Techniques and Equipment21

Cytogenetic Analysis Treatment Outcome Remission Induction Drug Approval Disease-Free Survival Administration, Oral Survival Analysis Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Prognosis Treatment Failure Salvage Therapy In Situ Hybridization, Fluorescence Reverse Transcriptase Polymerase Chain Reaction Survival Rate Inhibitory Concentration 50 Follow-Up Studies Neoadjuvant Therapy Blood Cell Count Immunohistochemistry Combined Modality Therapy

Phenomena and Processes16

Drug Resistance, Neoplasm Genes, abl Philadelphia Chromosome Dose-Response Relationship, Drug Apoptosis Cell Proliferation Phosphorylation Drug Synergism Mutation Time Factors Gene Expression Regulation, Leukemic Chromosomes, Human, Pair 9 Inhibitory Concentration 50 Signal Transduction Cell Survival Blood Cell Count

Disciplines and Occupations2

Cytogenetics Immunohistochemistry

Anthropology, Education, Sociology and Social Phenomena2

Drug Approval United States Food and Drug Administration

Information Science1

Health Care7

Treatment Outcome Disease-Free Survival Survival Analysis United States Food and Drug Administration Treatment Failure Survival Rate Follow-Up Studies

Anatomy Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Information Science Health Care

Benzamides Leukemia, Myelogenous, Chronic, BCR-ABL Positive Piperazines Pyrimidines Gastrointestinal Stromal Tumors Fusion Proteins, bcr-abl Antineoplastic Agents Proto-Oncogene Proteins c-kit Protein Kinase Inhibitors Receptor, Platelet-Derived Growth Factor alpha Leukemia, Myeloid, Chronic-Phase Receptor, Platelet-Derived Growth Factor beta Blast Crisis Drug Resistance, Neoplasm Genes, abl Hypereosinophilic Syndrome Cytogenetic Analysis Proto-Oncogene Proteins c-abl Protein-Tyrosine Kinases Hypopigmentation K562 Cells Gastrointestinal Neoplasms Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative Philadelphia Chromosome Treatment Outcome Remission Induction Receptors, Platelet-Derived Growth Factor Dermatofibrosarcoma Mastocytosis, Systemic Drug Approval Enzyme Inhibitors Pregnatrienes Cell Line, Tumor Fibromatosis, Aggressive Thiazoles Dose-Response Relationship, Drug Proto-Oncogene Proteins c-sis Disease-Free Survival Harringtonines Leukemia, Myeloid, Accelerated Phase Apoptosis Lichenoid Eruptions Cell Proliferation Interferon-alpha Administration, Oral mRNA Cleavage and Polyadenylation Factors Phosphorylation Neoplasm, Residual Drug Synergism Mutation Ketones Time Factors Gene Expression Regulation, Leukemic Cytogenetics Survival Analysis Antineoplastic Combined Chemotherapy Protocols Furans Pyrroles Drug Administration Schedule United States Food and Drug Administration Prognosis Rifabutin Treatment Failure Salvage Therapy Primary Myelofibrosis Disease Progression Chromosomes, Human, Pair 9 In Situ Hybridization, Fluorescence Hydroxyurea Neoplastic Stem Cells STAT5 Transcription Factor Platelet-Derived Growth Factor Reverse Transcriptase Polymerase Chain Reaction Survival Rate Recurrence Scleroderma, Systemic Histiocytoma, Malignant Fibrous Precursor Cell Lymphoblastic Leukemia-Lymphoma Stem Cell Factor Inhibitory Concentration 50 Signal Transduction Myeloid Progenitor Cells RNA, Messenger Follow-Up Studies Fibrosis Indoles Neoadjuvant Therapy Graves Ophthalmopathy Cell Survival Blood Cell Count Oncogene Proteins, Fusion Immunohistochemistry Combined Modality Therapy Antigens, CD34 Cells, Cultured

No FAQ available that match "phase patients receive oral imatinib mesylate"